Bankruptcy Exit Slashes Debt and Sets This Chipmaker Up for an EV Supercycle

Once written off, this chipmaker just pulled off a dramatic comeback by soaring over 1,600%.

Debt cleared, strategy reset, and early momentum is already catching the market’s attention, as the company eyes EV dominance.

On Behalf of The FUTR Corp.

Most “next big AI” stories are still burning cash.

But not this one.

The foundation is already in place:

Now comes the real catalyst.  The rollout of consumer AI agents.

Agents that can read your bills, flag your renewals, pay your obligations, and reward you for sharing your structured, verified data.

Every bill, contract, and policy hides valuable zero-party data. A new payments backbone combined with a Utility Token unlocks it, creating a consent-driven marketplace where every transaction generates recurring revenue.

This isn’t just another startup promise. It’s a scaled, profitable engine ready to tap one of the fastest-growing markets of the decade.

And right now, the market hasn’t priced it in.

Click here to get the name and stock symbol before it does.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Wall Street started the week off on the right foot as investors looked ahead to this week’s key jobs report and remained hopeful for Fed rate cuts despite the threat of a government shutdown.

Electronic Arts (NASDAQ: EA), the studio behind Battlefield and Madden, is going private in a jaw-dropping $55 billion buyout.

That makes it the largest leveraged buyout ever, with a mix of $36 billion in cash and $20 billion in debt powering the deal.

If you’re wondering why anyone would throw that much money at a video game company, it comes down to franchises.

When you own sports titles that sell every year and shooters with global followings, you’re basically printing a subscription to steady cash.

Debt Is the Final Boss

Here’s the catch: $20 billion in debt isn’t small change. History shows these mega-deals can crash hard — remember Toys “R” Us or Hertz? The new owners are betting you’ll keep buying the next Battlefield and FIFA, giving them the cash to keep the lights on.

You don’t need to crunch numbers to get it: if gamers show up, the debt monster stays fed. 

If they don’t, this could go down as another billion-dollar cautionary tale.

Why It’s More Than Just Games

This isn’t just about one studio; it’s about proving that blockbuster gaming IPs are still top-shelf media.

Private money is taking risks that Wall Street wouldn’t, and EA just became the case study.

So, the next time you fire up Madden, remember that you’re not just playing a game.

You’re helping decide whether the biggest buyout in history becomes a victory royale or a rage-quit.

AbbVie (NYSE: ABBV) is rolling out its ovarian cancer drug Elahere in the UK, and here’s the twist: it’s charging the same sticker price it does in the U.S.

Usually, Europe haggles prices way down, but this time AbbVie walked in like, “take it or leave it.”

If you’ve ever wondered how far pharma will push, this is it. The UK’s NHS is used to cutting deals, but AbbVie is daring regulators to pay up for next-gen medicine without a markdown.

Why This Move Hits Different

This isn’t just about one drug; it’s about testing how much pricing power a company really has.

If governments accept U.S.-level prices abroad, you suddenly change the whole global playbook.

And for you, that means watching whether healthcare systems blink. If they pay, it proves drugmakers can stretch their margins worldwide.

If they don’t, you get another front-page fight about affordability. Either way, you can’t ignore it.

The High-Stakes Bet

Elahere belongs to a buzzy class of therapies nicknamed “guided missiles,” because they target cancer cells while leaving healthy ones alone.

That kind of science usually gets fast adoption — and premium pricing to match.

The risk? Negotiations could still force AbbVie to trim the bill.

But if it pulls this off, it sets a precedent you’ll hear about every time a new cancer drug hits Europe. Sometimes the biggest drama isn’t in the lab, it’s in the invoice.

This brand's not Nike-and that's the point.

It's fast, tech-driven, and built for viral drops.

Now, it has equity backing from one of college sports' most iconic names.

Find out why Bama is betting on this company

Costco (NASDAQ: COST) has a tradition of dropping special dividends around the holidays, and the buzz is building again.

Think of it like Costco’s version of stuffing your stocking — but instead of candy canes, it’s cash.

The company has built up a monster cash pile from steady sales, and history says when the vault gets this full, members aren’t the only ones who score perks.

You might be shopping for pumpkin pies, but Costco could be shopping for ways to send you a payout.

Why Costco Can Pull This Off

The secret sauce is how consistently the retailer churns out growth. Same-store sales keep climbing, memberships renew like clockwork, and new stores keep popping up.

When you’ve got people lining up for bulk toilet paper and $1.50 hot dogs, the cash register doesn’t stop ringing.

That steady flow gives Costco room to expand and still hand out one-off bonuses.

You don’t need to see all the financial tables to know this is a company that prints cash — and sometimes shares it.

So What’s the Play Here?

You don’t have to be an analyst to get the story: Costco’s business is boring in the best way possible, and boring means predictable.

Predictable means it can afford holiday generosity without sweating the bill.

So if you’re watching from the sidelines, here’s the fun part: your cart might be filled with rotisserie chickens, but your account could soon get a little something extra, too.

Costco doesn’t just sell bulk — it sometimes delivers bonuses in bulk as well.

👉 Click here to get our closing report to your cell for free!

Wolfspeed Inc [WOLF] $21.62 (+1,686.78%)

Wolfspeed exploded following news that the company will emerge from bankruptcy with reduced debt, new leadership, and plans to refocus on EV chips.

Enanta Pharmaceutica [ENTA] $15.16 (+91.90%)

Enanta rose on promising Phase 2b results for zelicapavir, which delivered strong antiviral effects and improved recovery times in vulnerable RSV patients.

comScore Inc [SCOR] $8.85 (+42.51%)

comScore jumped after announcing a recapitalization deal that eliminates costly dividends, simplifies its capital structure, and aligns shareholder interests.

MoonLake Immunotherapeutics [MLTX] $6.25 (-89.93%)

MoonLake shares collapsed after its Phase 3 trial for sonelokimab in HS missed key efficacy expectations, casting doubt on its approval path.

Maplebear Inc [CART] $37.92 (-10.40%)

Maplebear (Instacart) shares fell nearly 9% as a new Kroger-DoorDash partnership intensified competitive threats, raising red flags over Instacart’s long-term positioning.

Forward Industries Inc [FORD] $26.51 (-9.31%)

Forward Industries' stock dipped due to its exposure to Solana and plans to tokenize its shares, with investors concerned about volatility in SOL and dilution risks from on-chain transitions.

One day the Dow drops 400+ points… the next, it surges 600+.

How do you trade in an environment like this? With options.

Our free ebook, Mastering Options Trading: A Beginner’s Guide, shows you exactly how to profit in wild markets.

From steady income tactics to advanced growth setups, it’s packed with proven strategies you can put to work right away.

[Get instant access here]—no cost, no catch.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.